NEW YORK (TheStreet) -- CHANGE IN RATINGS:Abbott Laboratories ( ABT) was downgraded at Deutsche Bank from buy to hold. Valuation call, based on a $33 price target, Deutsche said. Aruba Networks ( ARUN) was upgraded at Stifel Nicolaus from hold to buy. $27 price target. Growth could re-accelerate in 2013, Stifel Nicolaus said. The Bank of New York Mellon ( BK) was downgraded at Citigroup to neutral from buy. Valuation call, Citi said. BancorpSouth ( BXS) was downgraded at Keefe, Bruyette & Woods from market perform to underperform. Valuation call, based on a $12 price target, KBW said. Cardinal Health ( CAH) was upgraded at Mizuho from neutral to buy. $46 price target. Company will likely renew two major contracts in 2013, Mizuho said. Continental Resources ( CLR) was initiated with a buy rating at Deutsche Bank. $94 price target. Solid Bakken position can continue to drive growth, Deutsche said. Cepheid ( CPHD) was downgraded at Piper Jaffray from overweight to neutral. $34 price target. See further downside potential to near-term results, Piper Jaffray said. Endo Pharmaceuticals ( ENDP) was downgraded at Piper Jaffray from overweight to neutral. Opana ER is facing generic competition, Piper Jaffray said. $28 price target. Esco Technologies ( ESE) was upgraded at Robert Baird from neutral to outperform. $52 price target. Company should see higher orders in the near term, Robert Baird said. Edwards Lifesciences ( EW) was initiated with a market perform rating at JMP Securities. Company trades at a premium to its peers but has limited upside earnings potential, JMP said. East West Bancorp ( EWBC) was upgraded at Sterne Agee to buy from neutral. $26 price target. Earnings power from expense management, Sterne Agee said. FactSet Research Systems ( FDS) was initiated at Goldman Sachs with a sell rating. $79 price target. Slowing growth and emerging competition, Goldman said. Freescale ( FSL) was downgraded at JP Morgan to neutral. Company could see lower demand and lacks near-term catalysts, JP Morgan said. Illumina ( ILMN) was upgraded at Piper Jaffray from neutral to overweight. $61 price target. Company can continue to gain market share in next-generation sequencing, Piper Jaffray said. Johnson & Johnson ( JNJ) was upgraded at Deutsche Bank to buy. $82 price target. Company has a diversified business and deserves to trade at a premium valuation, Deutsche said.
Stock Comments / EPS ChangesDow Chemical ( DOW) numbers were raised at Jefferies. Shares are now seen reaching $34. Estimates were also raised on falling feedstock prices, Jefferies said. Hold rating. Eastman Chemical ( EMN) numbers were raised at Jefferies. Shares are now seen reaching $71. Estimates also raised on lower priced feedstocks, Jefferies said. Hold rating. Endo Health Solutions ( ENDP) numbers were lowered at Oppenheimer. Shares are now seen reaching $32. Estimates were also lowered on generic competition. Outperform rating. Endo Health Solutions numbers were lowered at UBS. Shares are now seen reaching $40. Estimates were also lowered on 2013 guidance, UBS said. Buy rating. Family Dollar ( FDO) numbers were cut at Credit Suisse. Shares are now seen reaching $65. Estimates were also reduced, given the company's new guidance, Credit Suisse said. Outperform rating. Kohl's ( KSS) estimates, target were reduced at Nomura. Estimates were reduced through 2013. Comp sales will likely fall with inventory levels, Nomura said. Neutral rating and new $41 price target. Limited Brands ( LTD) numbers lowered at Nomura. Shares are now seen reaching $52. Estimates were also cut, as the company is seeing lower sales, Nomura said. Buy rating. PPG ( PPG) numbers were raised at UBS. Shares are now seen reaching $136. Estimates were also raised on Deco paints deal, UBS said. Neutral rating. Valero ( VLO) price target was raised at Oppenheimer. Shares are now seen reaching $40. New projects improve outlook, Oppenheimer said. Outperform rating. >To submit a news tip, email: email@example.com.
Twitter and become a fan on Facebook.